What the trial was testing
The trial enrolled 130 patients with leukemia. The study was sponsored by Fred Hutchinson Cancer Center and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
95% of patients successfully engrafted their new cord blood cells, with 66% surviving three years.
Blood advances · 2020 · NCT00796068
These findings — that two-thirds of patients survived three years after transplant with this gentler regimen — were published in the Blood advances and represent the headline result of the study.
Researchers tracked outcomes across 130 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with leukemia, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This was a mid-stage study showing promising results with treosulfan-based conditioning before cord blood transplants. The treatment is not yet standard practice everywhere. If you're considering a cord blood transplant for leukemia or a related blood cancer, ask your transplant team whether treosulfan-based conditioning might be right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open leukemia trials
Registry of the German CLL Study Group
Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T/Natural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without T315I mutations in patients who has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.